rethinkPeptides Search
Menu
Study breakdown

Comprehensive AMP Review: From AI Design to Clinical Translation Barriers and Solutions

evidence
The takeaway

AMPs face clinical translation barriers (PK stability, specificity, immunocompatibility) addressable through ML/DL design, molecular simulation, and quantum computing, with this review bridging discovery to clinical practice.

Discovery → clinic gap

Despite thousands of AMPs discovered, very few reach patients — computational tools from ML to quantum computing aim to close this translational gap

What the researchers found

AMPs face clinical barriers (PK instability, poor specificity, immunogenicity) addressable through ML/DL-guided design, MD simulations, and emerging quantum computing, with an urgent need to integrate computational and experimental pipelines.

Why it matters

Despite thousands of known AMPs, very few reach clinical use. This review identifies the bottlenecks and the technologies that can overcome them.

How the study worked

Comprehensive review spanning AMP classification, mechanisms, bioinformatics platforms, computational design, clinical challenges, and frontier technologies.

What this study cannot tell us

Rapidly evolving field; some technology assessments may be outdated quickly. Clinical translation predictions are speculative for frontier technologies.

How to read the evidence

Comprehensive field review integrating fundamental science, computational advances, and clinical development perspectives.

When this study was published

Published in 2025.

The bigger picture

The convergence of AI, quantum computing, and peptide biology could finally break the clinical translation barrier that has limited AMP therapeutics for decades.

Questions still open

  • Which computational approach best predicts in vivo AMP efficacy?
  • When will quantum-enhanced peptide design produce clinical candidates?
  • Can standardized computational-experimental workflows accelerate AMP clinical trials?

Common questions

Why haven't more AMPs become drugs?
They work in the lab but break down too quickly in the body, don't reach their targets efficiently, and may trigger immune reactions. AI and computational tools are being used to solve these problems.
How does AI help develop antimicrobial peptides?
AI can screen millions of peptide sequences, predict which will kill bacteria, and optimize their stability and safety — tasks that would take decades by traditional methods.

Read the original research

Antimicrobial peptides: Bioinformatic advances and translational therapeutics to combat antibiotic resistance.

Advances in protein chemistry and structural biology, 149, 1-59

Citation

Haryini, Sree; Manku, Komalpreet Kaur; Deshkar, Aishwari; Doss C, George Priya. (2026). Antimicrobial peptides: Bioinformatic advances and translational therapeutics to combat antibiotic resistance.. Advances in protein chemistry and structural biology, 149, 1-59. https://doi.org/10.1016/bs.apcsb.2025.10.017